The combination of osimertinib and Tasher reduced the risk of death in lung cancer by 32% The combination of osimertinib (Tagriso) and Tasher (Orpatis) demonstrated a statistically significant advantage over chemotherapy in overall survival and progression-free survival in non-small cell lung cancer. AstraZeneca presented the results of the international phase III SAFFRON study at the ESMO 2026 Congress. The study included 338 patients with locally advanced or metastatic lung cancer with EGFR mutations and MET overexpression or amplification. All participants had disease progression after osimertinib treatment. The patients were divided into two groups: 171 received osimertinib in combination with questioning, and another 167 received platinum-based chemotherapy. The study met its primary and primary secondary endpoints: median overall survival was 17.8 months in the combination therapy group versus 12.9 months in the chemotherapy group. The risk of death decreased by 32% (HR 0.68; p=0.010). Median progression-free survival reached 7.6 versus 5.4 months, respectively. The risk of disease progression or death was reduced by 45% (HR 0.55; p 1 year after the start of treatment, 70% of patients who received the combination were alive compared to 53% in the control group. Progression-free survival at one year was 36% versus 10%. Side effects of grade three or higher, regardless of the causal relationship to the treatment, were recorded in 64% of the patients in the osimertinib and questioning group and in 63% in the chemotherapy group. The median duration of treatment was 8.5 and 3.5 months, respectively. The developers have not identified any new safety signals. Savolitinib is a MET inhibitor. Increased activity of this signaling pathway is one of the mechanisms by which tumors develop resistance to EGFR inhibitors, including osimertinib.

The combination of osimertinib and Tasher reduced the risk of death in lung cancer by 32% The combination of osimertinib (Tagriso) and Tasher (Orpatis) demonstrated a statistically significant advantage over chemotherapy in overall survival and progression-free survival in non-small cell lung cancer. AstraZeneca presented the results of the international phase III SAFFRON study at the ESMO 2026 Congress. The study included 338 patients with locally advanced or metastatic lung cancer with EGFR mutations and MET overexpression or amplification. All participants had disease progression after osimertinib treatment. The patients were divided into two groups: 171 received osimertinib in combination with questioning, and another 167 received platinum-based chemotherapy. The study met its primary and primary secondary endpoints: median overall survival was 17.8 months in the combination therapy group versus 12.9 months in the chemotherapy group. The risk of death decreased by 32% (HR 0.68; p=0.010). Median progression-free survival reached 7.6 versus 5.4 months, respectively. The risk of disease progression or death was reduced by 45% (HR 0.55; p 1 year after the start of treatment, 70% of patients who received the combination were alive compared to 53% in the control group. Progression-free survival at one year was 36% versus 10%. Side effects of grade three or higher, regardless of the causal relationship to the treatment, were recorded in 64% of the patients in the osimertinib and questioning group and in 63% in the chemotherapy group. The median duration of treatment was 8.5 and 3.5 months, respectively. The developers have not identified any new safety signals. Savolitinib is a MET inhibitor. Increased activity of this signaling pathway is one of the mechanisms by which tumors develop resistance to EGFR inhibitors, including osimertinib.